Curr Probl Cardiol. 2010 Mar;35(3):123-70. doi: 10.1016/j.cpcardiol.2009.11.002.
The platelet plays an essential role in atherothrombosis. Clinically, platelet-rich thrombi underlie acute coronary syndromes (ACSs). Current therapies have improved outcomes, however, often at the expense of increased risk of bleeding. With the increase in our understanding of the underlying pathophysiology of ACSs, newer targets for antiplatelet therapies continue to emerge. Novel antiplatelet agents may provide even greater reductions in ischemic events with the potential for less bleeding. This article reviews the evidence for current antiplatelet agents in ACSs as well as for the newer agents in later phases of clinical testing.
血小板在动脉血栓形成中起着至关重要的作用。临床上，富含血小板的血栓是急性冠状动脉综合征 (ACS) 的基础。目前的治疗方法已经改善了预后，但往往是以增加出血风险为代价的。随着我们对 ACS 潜在病理生理学的理解不断增加，抗血小板治疗的新靶点不断涌现。新型抗血小板药物可能会在降低缺血性事件发生率的同时减少出血。本文综述了 ACS 中现有抗血小板药物的证据，以及临床研究后期新型药物的证据。
